85277-87-8

Upstream product

• 85277-78-7 ethyl (E)-3-fluoro-2-phenylacrylate 
• 17097-90-4 2-phenylmalonic acid monoethyl ester 
• 101-97-3 Ethyl 2-phenylethanoate 
• 85277-71-0 1-tert-butyl 3-ethyl 2-(difluoromethyl)-2-phenylmalonate 
• 85278-30-4 ethyl 2-(tert-butoxycarbonyl)-2-(bromodifluoromethyl)phenylacetate 
• 85277-62-9 ethyl 2-(tert-butoxycarbonyl)phenylacetate 
• 16537-09-0 t-butyl phenylacetate 
• 85278-32-6 ethyl 2-phenyl-3,3-difluoroacrylate 

Downstream Products

• 843651-82-1 N-[(E)-(2-phenyl-3-fluoroallyl)]-N-tert-butoxycarbonylaminophthalimide 
• 879221-61-1 2-((Z)-2-Chloro-3-phenyl-allyl)-isoindole-1,3-dione 
• 93605-81-3 1,2-dibromo-1-fluoro-2-phenyl-3-phthalimidopropane 
• 85278-69-9 (E)-2-phenyl-3-fluoroallyl alcohol 
• 93605-75-5 2-phenyl-3-fluoroallylamine 
• 85278-44-0 1-fluoro-2-phenyl-3-phthalimidopropene 
• 85278-05-3 (E)-3-fluoro-2-phenylallylamine hydrochloride 
• 85278-84-8 (Z)-3-fluoro-2-phenyl-2-propenamine hydrochloride 
• 843651-83-2 1-[(E)-2-phenyl-3-fluoroallyl]-1-tert-butyloxycarbonylhydrazine 
• 85277-96-9 (E)-1-fluoro-2-phenyl-3-phthalimidopropene 

Relevant academic research and scientific papers

Novel arylalkenylpropargylamines as neuroprotective, potent, and selective monoamine oxidase B inhibitors for the treatment of Parkinson's disease

To develop novel neuroprotective agents, a library of novel arylalkenylpropargylamines was synthesized and tested for inhibitory activities against monoamine oxidases. From this, a number of highly potent and selective monoamine oxidase B inhibitors were identified. Selected compounds were also tested for neuroprotection in in vitro studies with PC-12 cells treated with 6-OHDA and rotenone, respectively. It was observed that some of the compounds tested yielded a marked increase in survival in PC-12 cells treated with the neurotoxins. This indicates that these propargylamines are able to confer protection against the effects of the toxins and may also be considered as novel disease-modifying anti-Parkinsonian agents, which are much needed for the therapy of Parkinson's disease.

NEW ARYLALKENYLPROPARGYLAMINE DERIVATIVES EXHIBITING NEUROPROTECTIVE ACTION FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES

The invention relates to novel arylalkenylpropargylamine derivatives of general formula (I) or enantiomers or diastereomers thereof or salts, optionally pharmaceutically acceptable salts, or solvates of any of these. The compounds can be used in treating or preventing a disease or condition in a mammal related to monoamine oxidase dysfunction, especially in neurodegenerative diseases, e.g. Parkinson's disease, Alzheimer's disease or Huntington's disease.

Inactivation of bovine plasma amine oxidase by haloallylamines

Various 2- and 3-haloallylamines were synthesized and evaluated as inhibitors of the quinone-dependent bovine plasma amine oxidase (BPAO). 3-Haloallylamines, which were previously found to be good inhibitors of the flavin-dependent mitochondrial monoamine

Enzyme-activated irreversible inhibitors of monoamine oxidase: Phenylallylamine structure-activity relationships

Seventeen 2-aryl-3-haloallylamine derivatives were prepared and evaluated as inhibitors of monoamine oxidase (MAO, EC 1.4.3.4). The synthesis of these compounds was achieved from either α-methylstyrene or ring-substituted phenylacetic acid derivatives. Wi

Allyl amine MAO inhibitors

Compounds of the formula STR1 wherein: R is phenyl, phenyl monosubstituted, disubstituted, or trisubstituted by (C1 -C8) alkyl, (C1 -C8)alkoxy, hydroxy, chlorine, bromine, iodine, fluorine, trifluoromethyl, nitr